Last June, we reported that Coherus BioSciences had received a Complete Response Letter (CRL) from the FDA for CHS-1701, a proposed biosimilar to Neulasta® (pegfilgrastim).  Later, in August, we reported that Coherus had anticipated resubmitting its BLA in response to the CRL.

Today, Coherus announced that it has resubmitted its BLA for CHS-1701.  According to Coherus’s press release, the BLA was submitted under the 351(k) pathway, and is supported by similarity data from analytical, pharmacokinetic, pharmacodynamics, and immunogenicity studies comparing CHS-1701 and Neulasta and integrates new immunogenicity data obtained from using a more revised immunogenicity assay.